In the past week, PACB stock has gone up by 3.11%, with a monthly gain of 8.74% and a quarterly surge of 22.09%. The volatility ratio for the week is 7.20%, and the volatility levels for the last 30 days are 9.52% for Pacific Biosciences of California Inc The simple moving average for the last 20 days is 0.37% for PACB stock, with a simple moving average of 2.86% for the last 200 days.
Is It Worth Investing in Pacific Biosciences of California Inc (NASDAQ: PACB) Right Now?
The stock has a 36-month beta value of 1.94. Opinions on the stock are mixed, with 6 analysts rating it as a “buy,” 1 as “overweight,” 8 as “hold,” and 0 as “sell.”
The public float for PACB is 241.81M, and at present, short sellers hold a 21.94% of that float. On January 06, 2025, the average trading volume of PACB was 9.43M shares.
PACB) stock’s latest price update
Pacific Biosciences of California Inc (NASDAQ: PACB)’s stock price has plunge by 10.56relation to previous closing price of 1.80. Nevertheless, the company has seen a 3.11% surge in its stock price over the last five trading sessions. globenewswire.com reported 2025-01-02 that MENLO PARK, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 4:30 PM PT (7:30 PM ET) in San Francisco, California.
Analysts’ Opinion of PACB
Jefferies, on the other hand, stated in their research note that they expect to see PACB reach a price target of $4. The rating they have provided for PACB stocks is “Buy” according to the report published on June 03rd, 2024.
PACB Trading at -0.33% from the 50-Day Moving Average
After a stumble in the market that brought PACB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -79.07% of loss for the given period.
Volatility was left at 9.52%, however, over the last 30 days, the volatility rate increased by 7.20%, as shares sank -4.33% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +10.56% upper at present.
During the last 5 trading sessions, PACB rose by +3.11%, which changed the moving average for the period of 200-days by -45.33% in comparison to the 20-day moving average, which settled at $1.9827. In addition, Pacific Biosciences of California Inc saw 8.74% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PACB starting from Kim Susan G., who sale 19,782 shares at the price of $1.72 back on Sep 30 ’24. After this action, Kim Susan G. now owns 695,654 shares of Pacific Biosciences of California Inc, valued at $34,065 using the latest closing price.
SUSAN KIM, the Officer of Pacific Biosciences of California Inc, proposed sale 19,782 shares at $1.72 during a trade that took place back on Sep 30 ’24, which means that SUSAN KIM is holding shares at $34,061 based on the most recent closing price.
Stock Fundamentals for PACB
Current profitability levels for the company are sitting at:
- -2.15 for the present operating margin
- 0.18 for the gross margin
The net margin for Pacific Biosciences of California Inc stands at -2.28. The total capital return value is set at -0.27. Equity return is now at value -64.80, with -23.55 for asset returns.
Based on Pacific Biosciences of California Inc (PACB), the company’s capital structure generated 0.66 points at debt to capital in total, while cash flow to debt ratio is standing at -0.26. The debt to equity ratio resting at 1.97. The interest coverage ratio of the stock is -26.21.
Currently, EBITDA for the company is -277.28 million with net debt to EBITDA at -2.63. When we switch over and look at the enterprise to sales, we see a ratio of 8.01. The receivables turnover for the company is 5.89for trailing twelve months and the total asset turnover is 0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.74.
Conclusion
To sum up, Pacific Biosciences of California Inc (PACB) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
